Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.08.01.667173

Nanoparticle-enabled plasma proteomics of a mouse atherosclerosis model

Abstract

BackgroundDyslipidemia, marked by elevated LDL-cholesterol (LDL-C), is a major risk factor for coronary heart disease. Mouse experimental models, such as Ldlr-/- mice that develop atherosclerosis and metabolic disorders when fed a high-fat diet (HFD), are indispensable for studying disease mechanisms and identifying potential biomarkers. ObjectivesWe aimed to profile the plasma proteins in experimental murine atherosclerosis with the primary goal of detecting low-abundant proteins. MethodsLdlr-/- mice were fed a chow diet or HFD for 3 (n = 27 per group) or 6 months (n = 12 per group). Plasma samples were processed using nanoparticle technology (Proteograph(R) XT Assay; Seer, Inc), and peptides were analyzed using the Orbitrap Astral (Thermo Fisher Scientific) in data-independent acquisition mode. For tissue proteomics, ten aortas were pooled for n = 4 pools per time point and diet, and n = 6 livers per time point and diet. Peptides were analyzed on the Orbitrap Exploris 480 in data-dependent mode. Proteomes were queried against the Tabula Muris mouse single-cell, STRING, and Gene Ontology databases, and queried against a genome-wide association list of 419 risk loci for coronary artery disease. ResultsWe sequenced 5,080 plasma proteins, surpassing previous reports by 10-fold. The prototypical apolipoproteins and complement factors were the most abundant proteins, whereas proteins associated with cytokine/chemokine signaling represented the previously uncharted mouse plasma proteome. We divided the proteome into quartiles (Q1-Q4) to monitor sweeping changes over time. Proteins with a sustained enrichment in HFD (n = 705) were indicative of liver cell subtypes (Tabula Muris). Whereas proteins that moved up from the lower quartiles - Q2 (n = 228), Q3 (115) and Q4 (63) - associated with leukocyte, fibroblasts, and endothelial cell markers, indicating that signatures of inflammation and endothelial activation increase with disease progression. Notably, 86 and 146 proteins were increased at 3 and 6 months, including MMP-12 and COL6A3. Classical apolipoproteins exhibited heterogeneous responses - SAA3 and APOC2 increased, while APOA1, APOE, and LCAT decreased with high-fat feeding, suggesting impaired high-density lipoprotein (HDL) functionality. Proteins shared between plasma and aorta were enriched for extracellular matrix components, while those overlapping with liver reflected metabolic processes. Finally, 120 coronary artery disease (CAD)-associated proteins from human GWAS were detected in Ldlr-/- plasma, of which 4, including lipoprotein lipase, exhibited an increase in abundance with HFD. ConclusionsNanoparticle-dependent proteome enrichment coupled to mass spectrometry may allow to identify novel plasma biomarkers in Ldlr-/- mice and facilitate monitoring of candidate proteins associated with human disease mechanisms in preclinical interventional studies, thereby opening new avenues for understanding disease pathology and uncovering novel molecular contributors.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Delwarde, C., Matamalas, J. T., Chelvanambi, S., Kasai, T., Shlayen, G., Santinelli-Pestana, D. V., Zamani, M., Aikawa, E., Aikawa, M., Singh, S. A.. 2025-08-02. Nanoparticle-enabled plasma proteomics of a mouse atherosclerosis model. https://doi.org/10.1101/2025.08.01.667173

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗

TREM2-stimulated, PDGF-dependent macrophage-fibroblast crosstalk induces beneficial plaque remodeling in clonal hematopoiesis

Background: In Jak2V617F clonal hematopoiesis, inflammatory signaling suppresses macrophage TREM2 and promotes features of plaque instability, while therapeutic TREM2 agonism reverses plaque instability by increasing fibroblasts and fibrous cap formation. We tested whether macrophage-derived PDGFB and stromal cell PDGFR? signaling mediate this response. Methods: Low allele burden (LAB) Jak2V617F atherosclerosis models were combined with inducible Pdgfb deletion in CX3CR1-lineage monocytes/macrophages or Pdgfra deletion in Col1a2-lineage fibroblast-enriched stromal cells. Mice were treated with the TREM2 agonist 4D9. Plaque composition, macrophage-fibroblast interactions, and aortic stromal cell populations were analyzed. Human WT and JAK2V617F iPSC-derived macrophages were used for validation. Results: TREM2 activation with 4D9 increased macrophage PDGFB production and promoted fibrous cap formation in LAB Jak2V617F atherosclerosis. Deletion of Pdgfb in CX3CR1-lineage cells markedly attenuated the 4D9-mediated increase in fibrous cap area and lesional PDGFR?+ cells, establishing macrophage-derived PDGFB as a key signal for the stromal response. Consistently, Col1a2-lineage Pdgfra deletion abolished the 4D9-induced fibrous cap response without significantly altering lesion or necrotic core area. Single cell RNA-seq identified increased Fmod+ and CD26/Dpp4+ fibroblast populations associated with 4D9 treatment. Fmod+ fibroblasts represented an abundant matrix-associated population, whereas CD26+ fibroblasts showed greatest enrichment, prominent extracellular matrix, collagen organization, and matrix-remodeling programs that were enhanced by 4D9 and attenuated by Pdgfra deletion. The stromal response was also associated with reduced macrophage migration-related programs and predicted chemokine communication from CD26+ fibroblasts to macrophages which was verified by macrophage migration studies. Moreover, stromal Pdgfra deletion increased lesional CCR2+ and CCR5+ macrophages. Conclusions: In a CH model of inflammatory atherosclerosis, TREM2 activation promotes a macrophage PDGFB-stromal PDGFR? pathway that expands Fmod+ and CD26+ fibroblast populations and increases fibrous cap matrix formation. CD26+ fibroblasts impair macrophage chemotaxis in a DPP4-dependent manner, suggesting reciprocal macrophage-fibroblast communication that coordinates matrix remodeling and inflammatory cell trafficking in the plaque.

pathology↗